Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 1
1988 1
2004 1
2007 1
2008 2
2009 1
2010 2
2012 1
2013 2
2014 2
2017 2
2018 1
2019 1
2020 3
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Montironi C, et al. Among authors: torrens l. Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23. Gut. 2023. PMID: 35197323 Free PMC article.
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Esteban-Fabró R, Willoughby CE, Piqué-Gili M, Montironi C, Abril-Fornaguera J, Peix J, Torrens L, Mesropian A, Balaseviciute U, Miró-Mur F, Mazzaferro V, Pinyol R, Llovet JM. Esteban-Fabró R, et al. Among authors: torrens l. Clin Cancer Res. 2022 Jun 1;28(11):2449-2460. doi: 10.1158/1078-0432.CCR-21-2517. Clin Cancer Res. 2022. PMID: 35302601 Free PMC article.
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, Llovet JM. Torrens L, et al. Hepatology. 2021 Nov;74(5):2652-2669. doi: 10.1002/hep.32023. Epub 2021 Sep 27. Hepatology. 2021. PMID: 34157147 Free article.
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Abril-Fornaguera J, Torrens L, Andreu-Oller C, Carrillo-Reixach J, Rialdi A, Balaseviciute U, Pinyol R, Montironi C, Haber PK, Del Río-Álvarez Á, Domingo-Sàbat M, Royo L, Akers NK, Willoughby CE, Peix J, Torres-Martin M, Puigvehi M, Cairo S, Childs M, Maibach R, Alaggio R, Czauderna P, Morland B, Losic B, Mazzaferro V, Guccione E, Sia D, Armengol C, Llovet JM. Abril-Fornaguera J, et al. Among authors: torrens l. Mol Cancer Ther. 2023 Apr 3;22(4):485-498. doi: 10.1158/1535-7163.MCT-22-0335. Mol Cancer Ther. 2023. PMID: 36780225 Free PMC article.
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.
Torrens L, Puigvehí M, Torres-Martín M, Wang H, Maeda M, Haber PK, Leonel T, García-López M, Esteban-Fabró R, Leow WQ, Montironi C, Torrecilla S, Varadarajan AR, Taik P, Campreciós G, Enkhbold C, Taivanbaatar E, Yerbolat A, Villanueva A, Pérez-Del-Pulgar S, Thung S, Chinburen J, Letouzé E, Zucman-Rossi J, Uzilov A, Neely J, Forns X, Roayaie S, Sia D, Llovet JM. Torrens L, et al. Clin Cancer Res. 2022 Oct 14;28(20):4509-4520. doi: 10.1158/1078-0432.CCR-22-0632. Clin Cancer Res. 2022. PMID: 35998012 Free PMC article.
Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.
Dalwadi DA, Torrens L, Abril-Fornaguera J, Pinyol R, Willoughby C, Posey J, Llovet JM, Lanciault C, Russell DW, Grompe M, Naugler WE. Dalwadi DA, et al. Among authors: torrens l. Mol Ther. 2021 Feb 3;29(2):680-690. doi: 10.1016/j.ymthe.2020.10.018. Epub 2020 Oct 22. Mol Ther. 2021. PMID: 33554867 Free PMC article.
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sàbat M, Abril-Fornaguera J, Akers N, Sala M, Ragull S, Arnal M, Villalmanzo N, Cairo S, Villanueva A, Kappler R, Garrido M, Guerra L, Sábado C, Guillén G, Mallo M, Piñeyro D, Vázquez-Vitali M, Kuchuk O, Mateos ME, Ramírez G, Santamaría ML, Mozo Y, Soriano A, Grotzer M, Branchereau S, de Andoin NG, López-Ibor B, López-Almaraz R, Salinas JA, Torres B, Hernández F, Uriz JJ, Fabre M, Blanco J, Paris C, Bajčiová V, Laureys G, Masnou H, Clos A, Belendez C, Guettier C, Sumoy L, Planas R, Jordà M, Nonell L, Czauderna P, Morland B, Sia D, Losic B, Buendia MA, Sarrias MR, Llovet JM, Armengol C. Carrillo-Reixach J, et al. Among authors: torrens l. J Hepatol. 2020 Aug;73(2):328-341. doi: 10.1016/j.jhep.2020.03.025. Epub 2020 Mar 30. J Hepatol. 2020. PMID: 32240714 Free article.
Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.
Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, Llovet JM. Bassaganyas L, et al. Among authors: torrens l. Clin Cancer Res. 2020 Dec 1;26(23):6350-6361. doi: 10.1158/1078-0432.CCR-20-1497. Epub 2020 Sep 1. Clin Cancer Res. 2020. PMID: 32873569 Free PMC article.
27 results